Prevalence Of Syndrome In Patients Research Articles

P.4.a.005 The prevalence of metabolic syndrome in patients with obsessive-compulsive disorder: a cross-sectional analysis

P.4.a.005 The prevalence of metabolic syndrome in patients with obsessive-compulsive disorder: a cross-sectional analysis

Prevalence of Metabolic Syndrome in Patients With Intermittent Claudication and its Correlation With the Segment of Arterial Obstruction

The metabolic syndrome (MetS) is associated with increased cardiovascular morbidity and mortality. Intermittent claudication reflects the presence of peripheral arterial disease (PAD). The aim of this study is to determine the prevalence of the MetS in claudicants and its correlation with age, gender, localization of arterial obstruction, and symptomatic coronary disease. Patients (n = 170) with intermittent claudication were studied. The mean age was 65 years (33-89). Metabolic syndrome was diagnosed in 98 patients (57.6%). The mean age of patients with MetS was 63.5 years compared with 67.0 years for patients without MetS (P = .027). Considering patients aged ≥65 years, MetS was present in 46 (48.9%) individuals and in 52 (68.4%) patients younger than 65 years (P = .011). Metabolic syndrome must be actively searched for in claudicant patients.

Serum uric acid is associated with common cardiovascular risk factors in Uygur population

Objective: To assess the prevalence of metabolic syndrome in patients with essential hypertension and to explore the inter-relationships between differentmetabolic factors andessential hypertension.Designandmethods: 1517 consecutive patients (811 men) were recruited in the Hypertension Clinic of BangaBandhu Sheikh Mujib Medical University (BSMMU), Dhaka, BangladeshfromApril2000toMarch2003.Metabolicsyndromewasdefined asco-occurrenceofanythreeof the followingtraits: abdominalobesity(waist circumference >102 cm in men and 88 cm in women), abnormal fasting serum level of glucose (≥110mg/dL), triglycerides (≥150mg/dL) and high density lipoprotein cholesterol (≤40mg/dL in men and <50mg/dL in women). Hypertensionwas common to all subjects and defined as the blood pressure≥140/90mmHg or the use antihypertensive medications. Results: All traits were present in 1.1% men and 12.8% women. Combination of different three traits were present as follows; hypertension with high triglyceride and low HDL (men 29.4% vs. women 51.8%), hypertension with highbloodglucoseand lowHDL(men13.5%vs.women29.8%),hypertension with high glucose and high triglyceride (men 18.1% vs. women 18.1%), hypertensionwith high blood glucose and largewaist (men 2.7% vs. women 25.7%), hypertension with high triglyceride and large waist (men 3.4% vs. women39.3%) andhypertensionwith lowHDLand largewaist (men2.5%vs. women70.6%).Conclusion:Thisstudyshowsthat themetabolic syndromeis highly prevalent among hypertensive patients especially women.

Prevalence of Restless Leg Syndrome in Patients With Functional Bowel Disease in the Community

Prevalence of Restless Leg Syndrome in Patients With Functional Bowel Disease in the Community

High Prevalence of Metabolic Syndrome in Patients with Barrett's Esophagus: A Multi-Center, Registry Study

High Prevalence of Metabolic Syndrome in Patients with Barrett's Esophagus: A Multi-Center, Registry Study

The metabolic syndrome and schizophrenia

To summarize the accumulated data on metabolic syndrome prevalence in patients with schizophrenia, examine evidence for a biological contribution of the mental illness to metabolic risk and review novel options available for management of prediabetic states. A Medline search using metabolic syndrome, insulin resistance and insulin sensitivity cross-referenced with schizophrenia was performed on articles published between 1990 and May 2008. Recent evidence indicates that schizophrenia increases predisposition towards metabolic dysfunction independent of environmental exposure. Both fasting and non-fasting triglycerides have emerged as important indicators of cardiometabolic risk, while metformin, thiazolidinediones and GLP-1 modulators may prove promising tools for managing insulin resistance. Because of lifestyle, disease and medication effects, schizophrenia patients have significant risk for cardiometabolic disease. Routine monitoring, preferential use of metabolically neutral antipsychotics and lifestyle education are critical to minimizing risk, with a possible role for antidiabetic medications for management of insulin resistant states that do not respond to other treatment strategies.

23: The effect of ABT-335 (fenofibric acid) on the prevalence of metabolic syndrome in patients with mixed dyslipidemia

23: The effect of ABT-335 (fenofibric acid) on the prevalence of metabolic syndrome in patients with mixed dyslipidemia

Audit of metabolic syndrome in adults prescribed clozapine in community and long-stay in-patient populations

Aims and MethodsTo calculate the prevalence of metabolic syndrome in patients receiving clozapine in community and long-stay in-patient settings. Patients were assessed using measures specified by the Expert Panel of the US National Cholesterol Education Program.ResultsThe prevalence of the metabolic syndrome was calculated as 53% in the community groups and 11% in the in-patient group, although both sample sizes (particularly the in-patient group) were small. Women were more frequently affected than men in the community population.Clinical ImplicationsThe higher percentage of metabolic syndrome in the community patients receiving clozapine has implications with respect to physical health. The reasons for the lower percentage in the in-patient group are unclear. Our findings point to a possible difference in the physical health of long-stay psychiatric in-patients and patients in the community.

Metabolic syndrome in patients with bipolar disorder

Background:Previous studies on the prevalence of metabolic syndrome in patients with bipolar disorder have reported higher rates than in their respective general populations.Objective:This study evaluates the prevalence rate and modal subcomponents of metabolic syndrome in 34 patients treated in University Hospital Centre Zagreb,Croatia.Method:Naturalistic, cross sectional study. Patients were evaluated for the presence of metabolic syndrome according to NCEP ATP-III criteria.Results:Mean age was 41.1(SD 12.9). Overall prevalence rate of MetS was 35.3%. Forty seven percent met the criterion for abdominal obesity, 58.8% for hypertrigliceridemia, 23.5 % for low HDL cholesterol, 50.0% for hypertension, and 23.5 for high fasting glucose. There was no diference in the prevalence rate by gender.Conclusions:Clinical medical monitoring for these parameters is recommended. Psychotropic drugs use may confer differential risk for developing the metabolic syndrome.

Obstruktive Schlaf-Apnoe und metabolisches Syndrom

Metabolic syndrome, i. e., the combined occurrence of obesity, arterial hypertension, insulin resistance and dyslipidaemia (increased triglycerides, reduced HDL cholesterol), is associated with a marked increase in cardiovascular risk. The prevalence of metabolic syndrome in patients with obstructive sleep apnoea (OSA) is very high. Obesity is the main risk factor for OSA and OSA itself is now considered to be the most frequent cause of secondary arterial hypertension. Due to the confounding influence of obesity, the causal connection between OSA and metabolic disturbances is less well established, however, epidemiological data are at least in favour of an independent link between OSA and insulin resistance. It is known that CPAP therapy can ameliorate OSA-associated hypertension. In contrast, the effects of CPAP treatment on insulin resistance and dyslipidaemia have to be further elucidated by large, randomised interventional trials.

Prevalence of the Metabolic Syndrome in Patients with Acute Myocardial Infarction

Prevalence of the Metabolic Syndrome in Patients with Acute Myocardial Infarction

Evaluation of the neurological involvement and prevalence of the carpal tunnel syndrome in patients with type-2 diabetes mellitus

Objective: to determine the frequency of the carpal tunnel syndrome (CTS) in patients with type 2 diabetes mellitus, verify whether it is associated with diabetic neuropathy (DN) and identify ways to recognize both by examining the upper limbs. Methods: The patients were submitted to anamnesis; the complaints were verified, tactile and vibratory sensitivity was evaluated, sensitive and motor nerve conduction (SMNC) was studied and Phalen’s test (PHT) was performed. The criteria for isolated CTS diagnosis were: alterations in the SMNC, complaints of paresthesia in the median nerve area and absence of either sensitive or motor alterations in the area of the ulnar nerve and lower extremities. Results: Of the 94 patients studied, 60 presented paresthesia. The SMNC study detected alterations in 88 patients (93.6%) and it was the most sensitive test. At the test to discriminate the two most static points (D2SP) we observed alterations in 47 patients and with the Semmes-Weinstein test detected alterations in 11 patients. Alterations were detected in 72 patients (76.6%) using the bioesthesiometer and in 04 patients using the diapason. PHT was positive in 33 patients. The correlation of the results showed that neural alterations were present in 92/94 patients; 11 patients presented alterations only in the median nerve and 81 patients presented combined alterations in the ulnar and median nerves. Only 4 patients presented CTS without subjacent neuropathy. Conclusions: The most sensitive tools were the bioesthesiometer and the D2SP. The neurophysiological examination demonstrated the presence of neuropathy subjacent to CTS. Clinical and neurophysiological criteria for CTS were presented by 31.91% of the patients; 27.66% with signs of subjacent neuropathy and 4.25% without diabetic neuropathy. Clinical criteria should be preponderant over the remaining tests and the neurophysiological test in order to characterize the carpal tunnel syndrome in the diabetic patient.

High prevalence of metabolic syndrome in patients with gout or SLE

High prevalence of metabolic syndrome in patients with gout or SLE

Analyzing the frequency and significance of the metabolic syndrome in patients with systemic lupus erythematosus

Evaluation of: Chung CP, Avalos I, Oeser A et al. High prevalence of the metabolic syndrome in patients with systemic lupus erythematosus: association with disease characteristic and cardiovascular risk factors. Ann. Rheum. Dis. 66(2), 208–214 (2007).Systemic lupus erythematosus is associated with higher rates of cardiovascular morbidity and mortality, related to accelerated atherosclerosis. This additional clinical complication can be attributed to traditional risk factors for atherosclerosis, use of corticosteroids and might also be the result of inflammatory mechanisms, all of which are aggravated in lupus patients. In this regard, inflammation is not only associated with systemic lupus patients but is also present in patients with metabolic syndrome and insulin resistance. The paper under evaluation examined the hypothesis that patients with lupus have a higher prevalence of the metabolic syndrome and that there is an association of the metabolic syndrome with other cardiovascular risk factors and inflammation.

Restless legs syndrome prevalence in patients on chronic hemodialysis in central Serbia

Restless legs syndrome (RLS) is a sensorymotor disorder and the core feature of this syndrome is a distressing, irresistible need or urge to move the legs. RLS is one of the most troublesome conditions experienced by endstage renal disease patients treated with regular hemodialysis, and is significantly associated with their increased mortality. The aim of this study was to assess the prevalence of RLS in the patients with end-stage renal failure in the three dialysis centers in central Serbia, and to investigate the association of the syndrome with clinical characteristics and biochemical variables. A cross-sectional multicentric study in which 166 consecutive hemodialysis patients were evaluated using a standard questionnaire based on diagnostic criteria elaborated by the International Restless Legs Syndrome Study Group was performed. All patients were reinterviewed and clinically examined by a qualified neurologist. The data on the patients with and without RLS were compared. The prevalence of RLS was 22.96% (95% CI, 16.57% to 29.35%). There was no significant difference in duration of hemodialysis and clinical characteristics when we compared the patients with RLS with those without RLS. We found significantly higher levels of blood urea nitrogen and creatinine and lower level of Kt/V index in the patients with RLS, which might point to inadequate dialysis in these patients. In our study the prevalence of RLS in the patients on the regular hemodialysis was 22.96%. The obtained results are similar to those of other studies using the same methodology in the white population on the regular hemodialysis.

Prevalence of Border-Line Metabolic Syndrome in Patients with Heart Failure

Prevalence of Border-Line Metabolic Syndrome in Patients with Heart Failure

Low Prevalence of Restless Legs Syndrome in Patients with Advanced Chronic Renal Failure in the Indian Population: A Case Controlled Study

Background: Restless legs syndrome (RLS) is reported to occur in 20–70% of uremic patients. There is no study from India regarding the prevalence of RLS in chronic renal failure (CRF) patients. Studies from other Asian countries have shown a much lower prevalence compared to the West. This study investigated the prevalence of RLS in patients with advanced CRF in the Indian population. Patients and Methods: Sixty‐five CRF patients and 99 controls were evaluated using a predesigned standard questionnaire. The control group consisted of prospective renal donors. Results: The mean age of our patients was 42.4 ± 14.9 years as compared to 43.7 ± 11.2 years (p = NS). The distribution of cause of CRF was as follows: diabetes 38.5%, hypertension 13.9%, chronic interstitial nephritis 29.2% and chronic glomerulonephritis 18.4%. RLS was present in 1 patient (1.5%) and none of the controls. Conclusion: The prevalence of RLS in CRF patients in India is very low as compared to the Western population.

A04-3 Prevalence of postural orthostatic tachycardia syndrome in patients with unexplained syncope. Clinical presentation and tilt test results

A04-3 Prevalence of postural orthostatic tachycardia syndrome in patients with unexplained syncope. Clinical presentation and tilt test results

A04-3 Prevalence of postural orthostatic tachycardia syndrome in patients with unexplained syncope. Clinical presentation and tilt test results

A04-3 Prevalence of postural orthostatic tachycardia syndrome in patients with unexplained syncope. Clinical presentation and tilt test results

Very high prevalence of sjogren syndrome in patients with HCV chronic hepatitis and cirrhosis

Very high prevalence of sjogren syndrome in patients with HCV chronic hepatitis and cirrhosis